文献速递胸部肿瘤

替雷利珠单抗联合化疗对比单纯化疗一线治疗晚期鳞状非小细胞肺癌:3期随机临床试验

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

这项在中国46个中心开展的开放标签3期随机试验纳入355例初治晚期鳞状非小细胞肺癌患者,比较替雷利珠单抗联合紫杉醇/卡铂(A组)、联合白蛋白紫杉醇/卡铂(B组)与单纯化疗(C组)。

要点

  • 替雷利珠单抗联合化疗较单纯化疗显著延长IRC评估的PFS,A组和B组均为7.6个月 vs 5.5个月。
  • 联合组IRC评估的ORR更高(A组72.5%、B组74.8% vs C组49.6%),缓解持续时间更长。
  • PD-L1表达水平与IRC评估的PFS或ORR未见关联,安全性总体可控。

核心结论

  • 在晚期鳞状非小细胞肺癌一线治疗中,替雷利珠单抗联合化疗较单纯化疗显著延长IRC评估的PFS并提高ORR,且安全性/耐受性可控,无论PD-L1表达水平。

研究设计与样本

  • 开放标签、随机3期临床试验,在中国46个中心开展,纳入初治、组织学确诊的IIIB/IV期鳞状非小细胞肺癌患者,按1:1:1随机分为三组。
  • 共355例患者接受治疗,中位年龄62岁(范围34-74岁),男性330例(91.7%)。
  • A组:替雷利珠单抗200 mg第1天+紫杉醇175 mg/m2第1天+卡铂AUC 5第1天,21天为一周期;B组:替雷利珠单抗+白蛋白紫杉醇100 mg/m2第1、8、15天+卡铂;C组:紫杉醇+卡铂。
  • 按疾病分期和肿瘤PD-L1表达(<1% vs 1%-49% vs ≥50%)分层。
  • 主要终点为独立评审委员会(IRC)评估的PFS;次要终点包括总生存期、研究者评估的PFS、IRC评估的ORR和缓解持续时间、不良事件发生率和严重程度。

主要发现

  • IRC评估的ORR在A组为72.5%、B组为74.8%,高于C组的49.6%;IRC评估的缓解持续时间在A组为8.2个月、B组为8.6个月,长于C组的4.2个月。
  • 未观察到PD-L1表达与IRC评估的PFS或ORR之间的关联。
  • 因不良事件中断任何治疗的患者比例:A组15例(12.5%)、B组35例(29.7%)、C组18例(15.4%)。
  • 每组最常见的≥3级不良事件为中性粒细胞减少,与已知化疗毒性一致;共发生6例导致死亡的治疗相关不良事件,但无死亡单独归因于替雷利珠单抗。

临床怎么用

  • 对于初治晚期鳞状非小细胞肺癌患者,可考虑替雷利珠单抗联合紫杉醇/卡铂或白蛋白紫杉醇/卡铂作为一线治疗选择。
  • PD-L1表达水平不宜作为筛选替雷利珠单抗联合化疗获益人群的依据。
  • 联合治疗期间需关注化疗相关骨髓抑制等不良事件,尤其含白蛋白紫杉醇方案的中断率较高。

局限性

  • 研究仅在中国进行,结果外推至其他人种或地区需谨慎。
  • 随访时间较短(中位8.6个月),总生存期数据尚未成熟。
  • 为开放标签设计,可能影响部分主观终点的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). OBJECTIVE: To assess the efficacy and safety/tolerability of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for patients with advanced sq-NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This open-label, randomized phase 3 clinical trial was conducted at 46 sites in China between July 2018 and June 2019 and included patients with treatment-naive, histologically confirmed stage IIIB/IV sq-NSCLC. The data cutoff for these analyses was December 6, 2019; data extraction occurred on January 7, 2020. INTERVENTIONS: Patients were randomized (1:1:1) to receive 1 of the following regimens intravenously on a 21-day cycle: tislelizumab (200 mg, day 1) plus paclitaxel (175 mg/m2, day 1) and carboplatin (area under the concentration of 5, day 1) (arm A); tislelizumab plus nab-paclitaxel (100 mg/m2, days 1, 8, and 15) and carboplatin (arm B); and paclitaxel and carboplatin (arm C). Patients were stratified by disease stage and tumor programmed cell death 1 ligand 1 (PD-L1) expression (<1% vs 1%-49% vs ≥50%). MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS) assessed by an independent review committee (IRC). Secondary end points included overall survival, investigator-assessed (INV) PFS, IRC-assessed objective response rate (ORR), and IRC-assessed duration of response, as well as the incidence and severity of adverse events (AEs). RESULTS: Overall, 355 patients (median [range] age, 62 [34-74] years; 330 men [91.7%]) with sq-NSCLC received treatment. After a median study follow-up of 8.6 months (95% CI, 8.1-9.0 months), IRC-assessed PFS was significantly improved with tislelizumab plus chemotherapy (arm A, 7.6 months; arm B, 7.6 months) vs chemotherapy alone (arm C, 5.5 months; hazard ratios were 0.524 (95% CI, 0.370-0.742; P < .001 [A vs C]) and 0.478 (95% CI, 0.336-0.679; P < .001 [B vs C]). Higher IRC-assessed ORR and longer IRC-assessed duration of response were observed in arms A (72.5%; 8.2 months) and B (74.8%; 8.6 months) vs C (49.6%; 4.2 months). No association was observed between PD-L1 expression and IRC-assessed PFS or ORR. Discontinuation of any treatment because of AEs was reported in 15 (12.5%; arm A), 35 (29.7%; arm B), and 18 (15.4%; arm C) patients. In each arm, the most common grade of 3 or greater AE was decreased neutrophil levels, which aligned with known chemotherapy toxic effects. Six treatment-related AEs leading to death occurred; however, no deaths were solely attributed to tislelizumab. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, adding tislelizumab to chemotherapy was associated with significantly prolonged IRC-assessed PFS, higher IRC-assessed ORRs, and a manageable safety/tolerability profile in patients with advanced sq-NSCLC, regardless of PD-L1 expression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03594747.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Wang J, Lu S, Yu X, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33792623. doi:10.1001/jamaoncol.2021.0366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。